Dermatology Form 1 Prescription Referral Form Bushnell: Phone: 1.352.793.8000

Fax: 1.352.793.8007 Wildwood:Phone: 1.352.748.9900

Fax: 1.352.748.9902





www.safescriptpharmacy.com

1. Patient inioni	lation									
Patient Name:								DOB:	1	
Address:			City:			State:		Zip:		
Home Phone:		Cell Phone	•			Email Addres				
Sex: □Male □Fer	nale Height:		Weight:	□ lbs. □ kį	g.	Known All	ergies:			
2. Insurance Information:										
Please fax front and back copy of all Insurance cards (Prescription and Medical)										
	ical Information:	,	•	,						
	clinical notes, labs, and t	ests with th	e prescriptio	n to expedite t	the P	rior Authoriza	ation			
Diagnosis: ICD 10:										
4. Prescription Information: For IV medications attach a copy of your prescription										
Medication	Dose/Strength		Sig						Qty	Refills
☐ Cosentyx®	□ 300mg		☐ Starter Dose: Inject 300mg SC at weeks 0, 1, 2, 3 and 4							
	☐ 150mg Sensoready Pen OR Prefilled Syringe		☐ Maintenance Dose: Inject 300mg SC every 4 weeks ☐ Other:							0
☐ Dupixent®	☐ 300mg/2mL Prefilled Syringe		☐ Starter Dose: 600mg SC divided in 2 different injection sites ☐ Maintenance Dose: 300mg SC every other week						2	0
☐ Enbrel®	G. , G		\square Starter Dose: Inject 50mg SC TWICE a week (72-96 hours apart for 3 months))		
	☐ 50mg/ml SureClick™ Autoinjector ☐ 25mg/0.5ml Prefilled Syringe		☐ Maintenance Dose: Inject 50mg SC ONCE a week							
☐ Humira* ☐ Humira*	☐ 20mg/0.4ml Prefilled Syringe ☐ 40mg/0.8ml Pen (2 doses)	(2 doses)	Starter Dose:	uppurativa: Inject 16	50mg S	C in day 1 then 80	mg on day 15			0 refills for
Citrate-Free	☐ 40mg/0.8ml Peri (2 doses)			sis: Inject 80mg SC d	_					starter dose
	☐ 40mg Kit 4x0.8ml			every 2 weeks there	eafter					
	☐ 40mg Starter Kit 6x0.8ml		Other:							
				Maintenance Dose:						
			☐ Hidradenitis Suppurativa: Inject 40mg SC on day 29 and then every week thereafter ☐ Plaque Psoriasis: Inject 40mg SC every 2 weeks							
☐ Siliq®	☐ 210mg/1.5mL Prefilled Syring	☐ Starter Dose: 210mg SC on weeks 0, 1, and 2, then maintenance thereafter								
			☐ Maintenance Dose: 210mg SC every 2 weeks							
☐ Stelara®	elara® ☐ 45mg/0.5ml Prefilled Syringe ☐ 90mg/1ml Prefilled Syringe		Starter Dose: ☐ Inject 45mg SC (patient ≤100 kg) at Day 1						□ 1	
			\square Inject 90mg SC (patient >100 kg) at Day 1							
				Maintenance Dose:						
				☐ Inject 45mg SC (patient ≤100 kg) On Day 29 and then every 12 weeks ☐ Inject 90mg SC (patient >100 kg) On Day 29 and then every 12 weeks						
			□ Other:							
☐ Taltz®	☐ Autoinjector 80mg/mL		☐ Starter Dose: 160mg SQ at week 0; then inject 80mg SQ at weeks 2, 4, 6, 8, 10, & 12					.0. & 12		
	☐ Prefilled Syringe 80mg/mL		☐ Maintenance Dose: 80mg SQ every 4 weeks							
☐ Tremfya®	☐ 100mg/ml Prefilled Syringe		☐ Starter Dose: Inject 100mg SC at weeks 0 & 4							
☐ Valchlor®	□ 0.016% gel		☐ Maintenance Dose: Inject 100mg SQ every 8 weeks ☐ Apply a thin film once daily to the affected areas of the body.							
			□ Other:							
Ship to:	☐ Patient ☐ Office	□ Other								
4. Physician Information:										
Prescriber Name:			Prescriber NPI: DEA#				EA#:			
Address:			City: State:					Zip:		
Primary Office Contact: Fax Number: Phone Number:										
Office Contact Em	ail:			ibil-	d alaza d	-1				
Prescriber Signature: Prescriber, please sign and date below *I authorize SafeScript Pharmacy and it's representatives to act as my authorized agent to secure coverage and initaite prior authorization process for my patient(s), and to sign any necessary forms on my behalf as authorized agents, including the recipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fullfill this										
prescription, I further authorize to forward this information and any related to coverage of the product to another pharmacy of patient's choice or in the patient's insurer's provider network.										
☐ Dispense as written ☐ Substitution Permissible										
Prescriber's Signature Date										
Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAD). If you are not the intended ercipient, please not the that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material. Thank you.										
RSP919 This prescription is valid only if transmitted by facsimile machine by a licensed prescriber.										